AcroMeta Group Limited (“AcroMeta”, or the “Company”, and together with its subsidiaries, the “Group”) today announced a strategic leap into the future of digital trade by entering into a Binding Indicative Term Sheet (the “Term Sheet”) with a technology partner (the “Partner”) for a proposed joint venture (the “Proposed JV”) on 29 November 2025.
The JV will be undertaken through its subsidiary, AcroMeta Lifestyle Pte. Ltd. (“AcroMeta Lifestyle”), which will be develop and provide an AI-powered global trade operating system.
This initiative marks a fundamental shift from passive online marketplaces to an active, intelligent platform that autonomously sources real-time global procurement opportunities and manages the entire trade execution process, including payment, logistics, and customs.
“This joint venture serves as the strategic launchpad for our AI-powered global trade operating platform. By deploying it first within our own ecosystem, we immediately generate a valuable, operational case study and revenue stream. Once we fine tune its efficacy, we will expand into other business, industrial sectors and countries,” Said Mr. Lawrence Toh, Executive Director.
From E-commerce to AI Trade Execution
The Proposed JV will fund the deployment of the AI-powered global trade operating system. This platform will utilize six specialized AI agent clusters—including Customs Data Intelligence, Social Intent Mining, and Government Tender AI—to continuously scan global data sources for verified purchase signals. Suppliers can pay to unlock these high-intent leads, and the platform offers a managed trade service, handling the complex cross-border execution.
JV Structure and Strategic Benefits
Under the Term Sheet, the paid-up capital of AcroMeta Lifestyle will be increased to S$500,000, with AcroMeta contributing S$200,000 for a 51% majority stake and the Partner contributing S$300,000. This structure enables AcroMeta to scale the venture with reduced capital outlay while retaining strategic control.
The technology Partner will assume the role of the general management, bringing day-to-day operational expertise, while AcroMeta maintains full oversight through board chairmanship and financial controls.
A Platform for Global Expansion
The Proposed JV marks a significant step in AcroMeta’s transformation and positions the Group to participate more meaningfully in global AI-driven markets. The Group aims to build new revenue pillars that complement its existing businesses and support sustainable shareholder value.
This media release is to be read in conjunction with SGXNET announcement released on the same date. Reference: https://tinyurl.com/283ykzm8
About AcroMeta Group Limited (SGX: 43F)
AcroMeta Group Limited (“AcroMeta” or the “Company”, and together with its subsidiaries, the “Group”), is in the business of facility management services. The Company has been listed on the Catalist board of the Singapore Exchange since 2016. For more information, please visit www.acrometa.com.
This media release has been reviewed by the Company’s Sponsor, W Capital Markets Pte. Ltd. (the “Sponsor”). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the “Exchange”), and the Exchange assumes no responsibility for the contents of this document, including the correctness of any of the statements or opinions made or reports contained in this document. The contact person for the Sponsor is Mr Foo Say Nam, 65 Chulia Street #43-01 OCBC Centre, Singapore 049513, telephone (65) 6513 3536.
– ACROMETA seeks to unlock value from its disposal of Life Science Incubator Holdings Pte. Ltd. following a strategic review. – ACROMETA’s wholly-owned subsidiary has entered into a non-binding MOU with a Malaysian sand concessionaire to facilitate further collaboration in mineral sand trading.
ACROMETA Group Limited (“ACROMETA”, or the “Company” and together with its subsidiaries, the “Group”), today announced that the Company has entered into a sale and purchase agreement (the “SPA”) for the disposal of all of the shares held by the Company (the “Sale Shares”) in Life Science Incubator Holdings Pte. Ltd. (“LSI”), representing 70% of the issued and paid-up share capital of LSI, for an aggregate consideration of S$2.7 million (the “Proposed Disposal”).
Mr Lawrence Toh, ACROMETA’s Executive Director, said, “The Proposed Disposal follows a strategic review of the Company’s long-term strategy and will enable ACROMETA to unlock value for future growth. We have determined that the Group’s resources and management efforts would be better directed towards other potential business opportunities in mineral sands trading.”
The Proposed Disposal will be made conditional upon approval by the shareholders of the Company at an Extraordinary General Meeting (“EGM”) to be convened in due course. Upon the completion of the Proposed Disposal, LSI will cease to be a subsidiary of the Group.
Mineral Sands Trading
AcroMeta Minerals Pte. Ltd. (“AcroMeta Minerals”), a wholly-owned subsidiary of the Company, has entered into a non-binding Memorandum of Understanding (“MOU”) with Constance Holding Sdn. Bhd. (“Constance Holding”) to facilitate further collaboration in mineral sands trading.
Constance Holding, a Malaysia-based holding company, operates primarily in the upstream sand industry. It holds exclusive rights to market, sell, and trade sand products from the concession and management rights of the sand concession. Constance Holding is currently involved in supplying sand for major land reclamation projects across major infrastructure developments in Malaysia.
This latest development represents another significant milestone in the Group’s ongoing pursuit of regional opportunities, following an earlier non-binding, non-exclusive MOU with PT Swadaya Buana Makmur for the supply of high-grade silica sand from West Kalimantan, Indonesia. The Group is actively engaged in negotiations with potential international buyers, with formal offtake agreements anticipated in the near future.
ACROMETA remains optimistic about the long-term prospects of AcroMeta Minerals, which are supported by strong demand and strategic local partnerships. With an enhanced cash position following the completion of the Proposed Disposal, the Group is well-positioned to continue exploring suitable new business opportunities that will create value for its shareholders.
This press release should be read in conjunction with the SGXNET announcement issued on the same date.
About ACROMETA Group Limited (SGX Stock Code:43F)
ACROMETA (Previously known as ACROMEC Limited) has been listed on the Catalist Board of the Singapore Exchange since 2016.
ACROMETA’s business is divided into three main business segments: (i) Maintenance and repair services of facilities and equipment of controlled environments and their supporting infrastructure, (ii) Co-working laboratory business, which currently operates 6,500 square feet of co-working laboratory space at The German Centre in Singapore and a 21,538 square feet coworking laboratory centre at Elementum, One-North, serving SMEs and startups, and (iii) Trading of minerals and sand. For more information, please visit www.acrometa.com .
Media and Analysts Contact:
ACROMETA Group Limited Ms. Cheah Lai Min Chief Financial Officer Tel: +65 6717 0111 Email: laimin.cheah@acrometa.com
This media release has been reviewed by the Company’s Sponsor, Evolve Capital Advisory Private Limited (the “Sponsor)”. It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the “SGX-ST”), and the SGX-ST assumes no responsibility for the contents of this media release, including the correctness of any of the statements or opinions made or reports contained in this media release.
The contact person for the Sponsor is Mr Jerry Chua (Tel: (65) 6241 6626), at 138 Robinson Road, Oxley Tower, #13-02, Singapore 068906.
ACROMETA Group Limited (“ACROMETA”, or the “Company” and together with its subsidiaries, the “Group”), an established specialist engineering service provider in the field of controlled environments serving mainly the healthcare, biotechnology, pharmaceutical, research and academia sectors, today announced the Company had on 19 January 2024 received an indicative non-binding letter of intent (the “LOI”) from AESM Holding Pte. Ltd. (the “Purchaser”) in relation to the sale and purchase of 100% of the issued share capital of its wholly-owned subsidiary, Acromec Engineers Pte Ltd (the “Buy-Out”).
The Parties on a best-effort basis endeavour to enter into the definitive agreement necessary to give effect to the Buy-Out transaction by 28 February 2024; or such later date as mutually agreed between the Parties. Shareholders of the Purchaser includes several key management personnel of the Target Company. If the Buy-Out is successfully concluded, the Group’s remaining core business would be its fastgrowing co-working laboratory space business (“CLSB”) via its 70%-owned subsidiary Life Sciences Incubator Holdings Pte Ltd (“LSI”). In addition, the Buy-Out is set to include the novation of LSI’s net debt, further strengthening the Group’s financial position. The Purchaser is also set to indemnify the Group following the Creditor’s Voluntary Liquidation of Neo Tiew Power Pte. Ltd. (“NTP”), in which the Company has a 56% effective interest.
Besides the Group’s current CLSB at The German Center Singapore which occupies an area of 6,500 sqft, the Group continues to collaborate with strategic partners to accelerate the growth of its CLSB:
– 6 April 2023 – LSI entered into a non-binding MOU with a renowned German commercial property management company to work together on LSI’s proposed co-working laboratory space project in the flourishing life sciences hub of Brisbane, Australia.
– 6 October 2023 – LSI entered into a Management Agreement with HB Universal Pte Ltd, a subsidiary of Mainboard-listed Ho Bee Land Limited. The MA engages LSI to operate and manage a co-working laboratory centre at Elementum, One-North, a building in the heart of Singapore’s biomedical industry district.
– 12 December 2023 – LSI entered into a strategic cooperation framework agreement with its partner Fenglin Healthcare Industry Development (Group) Co. Ltd., a company registered in the People’s Republic of China (“PRC”), to deepen their collaboration for the CLSB in the PRC.
Mr Levin Lee, ACROMETA’s Executive Chairman, said, “While the controlled environments engineering EPC (Engineering, Procurement, Construction) business still has growth potential, there will be ongoing margin pressures and challenging operating conditions, primarily due to increased costs in energy, manpower and construction materials. In particular, the availability of skilled manpower poses a challenge together with higher wages and higher dormitory space rental costs. Thus, we want to focus on the less capital-intensive and higher value-add co-working laboratory business to strengthen the Group’s performance.”
In another potential business opportunity, the Company incorporated AcroMeta Minerals Pte. Ltd. (“AcroMeta Minerals”) on 15 November 2023 as a follow-up to the 6 November signing of a non-binding non-exclusive MOU between AcroMeta and PT Swadaya Buana Makmur (“PTSBM”) for the supply of high purity (>99.5%) low iron silica sand from West Kalimantan, Indonesia.
The Company is confident in the long-term prospects of AcroMeta Minerals given the high demand for high purity silica sand which is used in the manufacture of solar panels, precision glass and ceramic instruments, ophthalmic lenses and LCD screens required by many industries such as the biotechnology, electronics, and pharmaceutical industries. The Group is currently negotiating with potential international buyers before entering into formal offtake agreements with PTSBM.
About ACROMETA Group Limited (SGX Stock Code:43F)
ACROMETA (Previously known as ACROMEC Limited) is an established specialist engineering services provider with more than 25 years of experience in the field of controlled environments.
The Group has, over the years, acquired expertise in the design and construction of facilities requiring controlled environments such as laboratories, medical and sterile facilities and cleanrooms.
ACROMETA’s business is divided into three main business segments: (i) Engineering, procurement, and construction services, specialising in architectural, and mechanical, electrical, and process works within controlled environments; (ii) Maintenance and repair services of facilities and equipment of controlled environments and their supporting infrastructure. (iii) Co-Working Laboratory business; currently operates 6,500 square feet of co-working laboratory space at The German Centre in Singapore, serving SMEs and startups.
The Group mainly serves the healthcare, biotechnology, pharmaceutical, research and academia, and electronics sectors. ACROMETA’s customers include hospitals and medical centres, government agencies, research and development companies or agencies, research and development units of multinational corporations, tertiary educational institutions, pharmaceutical companies, semiconductor manufacturing companies, and multinational engineering companies.
The Company has been listed on the Catalist board of the Singapore Exchange since 2016. For more information, please visit www.acrometa.com .
Media and Analysts Contact: ACROMETA Group Limited Ms. Cheah Lai Min Chief Financial Officer Tel: +65 6415 0574 Email: laimin.cheah@acrometa.com
This media release has been reviewed by the Company’s Sponsor, Evolve Capital Advisory Private Limited (the “Sponsor”). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the “Exchange”), and the Exchange assumes no responsibility for the contents of this document, including the correctness of any of the statements or opinions made or reports contained in this document.
The contact person for the Sponsor is Mr. Jerry Chua, 138 Robinson Road, #13-02 Oxley Tower, Singapore 068906, jerrychua@evolvecapitalasia.com .
ACROMETA Group Limited (“ACROMETA”, or the “Company” and together with its subsidiaries, the “Group”), an established specialist engineering service provider in the field of controlled environments serving mainly the healthcare, biotechnology, pharmaceutical, research and academia sectors, today announced that its 70% owned subsidiary Life Science Incubator Holdings Pte Ltd (“LSI”) signed a strategic cooperation framework agreement (“Agreement”) with its partner Fenglin Healthcare Industry Development (Group) Co. Ltd. (“Fenglin Group”).
(3rd from Right) Fenglin Group Deputy General Manager Mr Pan Taishen and (2nd from Right) AcroMeta Executive Chairman Mr Levin Lee Keng Weng at the signing ceremony
The Agreement follows an earlier MOU signed in November 2023 to further deepen their collaboration for the co-working laboratory space business in the People’s Republic of China.
The signing ceremony, which was held at the German Center Singapore, was part of a corporate access event which featured a presentation on the co-working laboratory space business, followed by a tour of the facilities for a first-hand look at the laboratory that is fully fitted with state-of-the-art equipment.
Representatives from AcroMeta, LSI and Fenglin Group present at the event held at the German Centre Singapore
China-incorporated Fenglin Group, the administrative arm of the Shanghai Xuhui government in charge of Life Sciences, aims to establish an integrated ecosystem of local and international stakeholders in Shanghai’s Xuhui District to accelerate biopharmaceutical innovation and development.
Fenglin Group will promote the co-working laboratory space with a focus on overseas biomedical science startups and SMEs planning to develop their business in China. On its part, LSI will use its existing business networks to recommend to Fenglin Group, Singapore and other overseas biomedical sciences companies that intend to have a business foothold in China and need co-working laboratory space.
Mr Levin Lee Keng Weng, ACROMETA’s Executive Chairman, said,
“We extend a warm welcome to all our honoured guests, including the top Management of Fenglin Group. LSI and Fenglin will work closely together to fulfil the goals of our strategic cooperation in the co-working laboratory business.
China’s life sciences industry is an important part of China’s ‘Made in China 2025’ strategy and its rapid growth has seen the birth of thousands of start- ups and SMEs in biotech, agritech, pharmaceuticals, and medical devices doing research and development to bring innovative products into the market. Our co-working laboratory space business will enable them to conduct their R&D without incurring high CAPEX to build the facilities.”
About ACROMETA Group Limited (SGX Stock Code:43F)
ACROMETA (Previously known as ACROMEC Limited) is an established specialist engineering services provider with more than 25 years of experience in the field of controlled environments.
The Group has, over the years, acquired expertise in the design and construction of facilities requiring controlled environments such as laboratories, medical and sterile facilities, and cleanrooms.
ACROMETA’s business is divided into three main business segments: (i) Engineering, procurement, and construction services, specialising in architectural, and mechanical, electrical, and process works within controlled environments; (ii) Maintenance and repair services of facilities and equipment of controlled environments and their supporting infrastructure. (iii) Co-Working Laboratory business; currently operates 6,500 square feet of co-working laboratory space at The German Centre in Singapore, serving SMEs and startups.
The Group mainly serves the healthcare, biotechnology, pharmaceutical, research and academia, and electronics sectors. ACROMETA’s customers include hospitals and medical centres, government agencies, research and development companies or agencies, research and development units of multinational corporations, tertiary educational institutions, pharmaceutical companies, semiconductor manufacturing companies, and multinational engineering companies.
The Company has been listed on the Catalist Board of the Singapore Exchange since 2016. For more information, please visit www.acrometa.com.
Media and Analysts Contact: ACROMETA Group Limited Ms. Cheah Lai Min Chief Financial Officer Tel: +65 6415 0574 Email: laimin.cheah@acrometa.com
This media release has been reviewed by the Company’s Sponsor, Evolve Capital Advisory Private Limited (the “Sponsor”). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the “Exchange”), and the Exchange assumes no responsibility for the contents of this document, including the correctness of any of the statements or opinions made or reports contained in this document.
The contact person for the Sponsor is Mr. Jerry Chua, 138 Robinson Road, #13-02 Oxley Tower, Singapore 068906, jerrychua@evolvecapitalasia.com.
ACROMETA Group Limited (“ACROMETA”, or the “Company” and together with its subsidiaries, the “Group”), an established specialist engineering service provider in the field of controlled environments serving mainly the healthcare, biotechnology, pharmaceutical, research and academia sectors, today announced its financial results for the 12 months ended 30 September 2023 (“FY2023”).
The Group’s revenue for FY2023 saw a 12% increase to S$69.5 million, a historical high for the Group, primarily attributed to the Engineering, Procurement and Construction (“EPC”) segment’s strong performance. Gross profit increased by 19% from S$9.8 million for FY2022 to S$11.7 million for FY2023, while gross profit margins improved from 15.7% for FY2022 to 16.8% in FY2023.
The Group’s continuing operations comprising of its specialist EPC and maintenance segments recorded a profit of S$2.2 million on the back of a 10.8% growth in revenue from S$62.3 million for FY2022 to S$69.0 million for FY2023. However, the operating environment remains challenging amidst increased operational costs in energy, labour, and materials as a result of inflationary pressures in the global economy.
In May 2023, the Group ventured into the co-working laboratory space segment through the acquisition of Life Science Incubator Pte Ltd (“LSI”), which currently manages a 6,500 sqft co-working laboratory space at The German Centre, Singapore. Under the Group’s leadership, LSI has made significant inroads with new partnerships across Singapore, Australia, and China for new co-working laboratory space projects, reflecting the Group’s continued efforts to broaden its revenue stream and capture new regional opportunities.
Mr Levin Lee Keng Weng, ACROMETA’s Executive Chairman, said,
“We will continue our current focus on expanding the laboratory construction and co-working laboratory space businesses, both of which are currently cash flow positive with promising long-term prospects amidst an encouraging flow of business opportunities and projects in the last twelve months.”
The Group’s co-working laboratory space segment contributed positively to AcroMeta’s FY2023 results and will be developed as a new engine of growth for the Group’s business moving forward.
While the Group’s continuing operations delivered a profit of S$2.2 million, the Group reported a net loss attributable to owners of S$7.5 million in FY2023 due to the one-off impairment and provisions. Excluding these, the net profit would be S$2.3 million compared to FY2022 net profit of S$2.9 million.
The one-off impairment and provisions relating to discontinuing operations related to renewable energy business are based on historical expenditure and have minimal impact on the Group’s ongoing cashflow. The Group’s net asset value remains positive at S$2.6 million or 0.93 cents per share as at 30 September 2023 while the Group’s cash and cash equivalents are stable at S$4.4 million as at 30 September 2023 as compared to S$4.1 million as at 30 September 2022. The proposed subscription of 12,500,000 shares in the capital of the Company for S$0.5 million, announced in November 2023, is expected to further strengthen the Group’s financial resources.
While renewable energy business is fundamentally promising, the Covid-19 pandemic’s impact on construction as well as regulatory changes meant that the project would continue to require financial support and affect the Group’s allocation of resources. The Group’s prudent step to place Neo Tiew Power Pte. Ltd. (“NTP”), a loss-making indirect subsidiary, under Creditors’ Voluntary Winding Up will enable optimal allocation of resources as the Group continues to progress forward with its specialist engineering and co-working laboratory space business.
This press release should be read in conjunction with the financial statements released by AcroMeta Group Limited today.
About ACROMETA Group Limited (SGX Stock Code:43F)
ACROMETA (Previously known as ACROMEC Limited) is an established specialist engineering services provider with more than 25 years of experience in the field of controlled environments.
The Group has, over the years, acquired expertise in the design and construction of facilities requiring controlled environments such as laboratories, medical and sterile facilities, and cleanrooms.
ACROMETA’s business is divided into three main business segments: (i) Engineering, procurement, and construction services, specialising in architectural, and mechanical, electrical, and process works within controlled environments; (ii) Maintenance and repair services of facilities and equipment of controlled environments and their supporting infrastructure. (iii) Co-Working Laboratory business; currently operates 6,500 square feet of co-working laboratory space at The German Centre in Singapore, serving SMEs and startups.
The Group mainly serves the healthcare, biotechnology, pharmaceutical, research and academia, and electronics sectors. ACROMETA’s customers include hospitals and medical centres, government agencies, research and development companies or agencies, research and development units of multinational corporations, tertiary educational institutions, pharmaceutical companies, semiconductor manufacturing companies, and multinational engineering companies.
The Company has been listed on the Catalist Board of the Singapore Exchange since 2016. For more information, please visit www.acrometa.com.
Media and Analysts Contact:
ACROMETA Group Limited Ms. Cheah Lai Min Chief Financial Officer Tel: +65 6415 0574 Email: laimin.cheah@acrometa.com
This media release has been reviewed by the Company’s Sponsor, Evolve Capital Advisory Private Limited (the “Sponsor”). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the “Exchange”), and the Exchange assumes no responsibility for the contents of this document, including the correctness of any of the statements or opinions made or reports contained in this document.
The contact person for the Sponsor is Mr. Jerry Chua, 138 Robinson Road, #13-02 Oxley Tower, Singapore 068906, jerrychua@evolvecapitalasia.com.
New strategic partnership reflects continued efforts to explore international expansion opportunities for the Group’s scalable and replicable co-working laboratory space business.
ACROMETA Group Limited (ACROMETA, or the Company and together with its subsidiaries, the Group), an established specialist engineering service provider in the field of controlled environments serving mainly the healthcare, biotechnology, pharmaceutical, research and academia sectors, today announced that its 70% owned subsidiary Life Science Incubator Holdings Pte Ltd (LSI) has entered into a strategic partnership with Fenglin Healthcare Industry Development (Group) Co. Ltd. (Fenglin Group) through a non-binding Memorandum of Understanding (Fenglin MOU) to develop new business opportunities for co-working laboratory space in the People’s Republic of China.
(Front L-R) Fenglin Group Deputy General Manager Mr Pan Taishen and AcroMeta Chairman Mr Levin Lee Keng Weng at the signing ceremony in Shanghai.
China-incorporated Fenglin Group, the administrative arm of the Shanghai Xuhui government in charge of Life Sciences, aims to establish an integrated ecosystem of local and international stakeholders in Shanghai’s Xuhui District to accelerate biopharmaceutical innovation and development.
Fenglin Group will promote the co-working laboratory space with a focus on overseas biomedical science startups and SMEs planning to develop their business in China. On its part, LSI will use its existing business networks to recommend to Fenglin Group, Singapore and other overseas biomedical sciences companies that intend to have a business foothold in China and need co-working laboratory space. An area of approximately 2,705 sqm is set to be leased by LSI at preferential rates to set up world-class co-working laboratory space at Fenglin Group’s Innovation Valley Life Sciences Hub to provide a cost-effective venue with comprehensive laboratory facilities and equipment for research and development.
Mr Levin Lee Keng Weng, ACROMETA’s Executive Chairman, said,
“AcroMeta will continue to capture business opportunities both in Singapore and beyond to grow and create sustainable shareholder value for its investors. The business model for the Group’s co-working laboratory space business is scalable and replicable and therefore eminently suitable for international expansion.”
“China’s biopharmaceutical industry has undergone a tremendous transformation to become a thriving innovative life sciences hub driven by investments in research and development. The sector is a key focus of the Chinese government’s Made in China 2025 strategy, and we are optimistic about LSI’s long-term growth potential in collaboration with local partners.”
LSI has also signed a non-binding Memorandum of Understanding (“JV MOU”) with three investor parties (“Investor Parties”) for the setting up of a Joint Venture company (“JV Company”) to define the structure, ownership, and operational aspects of the Fenglin MOU. The expected JV Company will have a paid-up capital of at least S$3 million, with LSI holding a 51% stake. The Investor Parties are all established businessmen with deep connections to China’s medical and life science industries and will contribute their business network, expertise, and experience to facilitate the smooth set-up and successful realisation of the Fenglin MOU’s objectives.
The Fenglin MOU reflects the Group’s continued efforts to broaden its revenue stream and capture new regional opportunities. Following the Group’s MOU for the supply of high-grade silica sand from Indonesia, AcroMeta has extended its MOU with its Thai partner to jointly pursue the design, construction and operation of a solid waste and sludge testing and certification laboratory.
ACROMETA (Previously known as ACROMEC Limited) is an established specialist engineering services provider with more than 25 years of experience in the field of controlled environments.
The Group has, over the years, acquired expertise in the design and construction of facilities requiring controlled environments such as laboratories, medical and sterile facilities, and cleanrooms.
ACROMETA’s business is divided into three main business segments: (i) Engineering, procurement, and construction services, specialising in architectural, and mechanical, electrical, and process works within controlled environments; (ii) Maintenance and repair services of facilities and equipment of controlled environments and their supporting infrastructure. (iii) Co-Working Laboratory business; currently operates 6,500 square feet of co-working laboratory space at The German Centre in Singapore, serving SMEs and startups.
The Group mainly serves the healthcare, biotechnology, pharmaceutical, research and academia, and electronics sectors. ACROMETA’s customers include hospitals and medical centres, government agencies, research and development companies or agencies, research and development units of multinational corporations, tertiary educational institutions, pharmaceutical companies, semiconductor manufacturing companies, and multinational engineering companies.
The Company has been listed on the Catalist Board of the Singapore Exchange since 2016. For more information, please visit www.acrometa.com.
Media and Analysts Contact: ACROMETA Group Limited Ms. Cheah Lai Min Chief Financial Officer Tel: +65 6415 0574 Email: laimin.cheah@acrometa.com
This media release has been reviewed by the Company’s Sponsor, Evolve Capital Advisory Private Limited (the “Sponsor”). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the “Exchange”), and the Exchange assumes no responsibility for the contents of this document, including the correctness of any of the statements or opinions made or reports contained in this document.
The contact person for the Sponsor is Mr. Jerry Chua, 138 Robinson Road, #13-02 Oxley Tower, Singapore 068906, jerrychua@evolvecapitalasia.com
ACROMETA signs MOU with PT. Swadaya Buana Makmur for the supply of high-grade silica sand from West Kalimantan.
Up to one million tonnes of supply annually targeted with an estimated open market value of US$39 million[1]
ACROMETA Group Limited (ACROMETA, or the Company and together with its subsidiaries, the Group), today announced that the Company has signed a Memorandum of Understanding (MOU) to pursue new business opportunities in Indonesia.
A non-binding non-exclusive MOU was signed between ACROMETA and PT. Swadaya Buana Makmur (PTSBM) for the supply of high-grade silica sand from West Kalimantan, Indonesia.
Subject to relevant export approvals, a new subsidiary set-up for the proposed business will target to purchase and PTSBM will target to supply an annual offtake of up to 1,000,000 tonnes of Low Iron Silica Sand with a guaranteed quality of at least 99.5% SIO2 at prices and payment terms in line with market conditions. Both parties are set to enter into definitive Offtake/Purchase Agreements with a target for the Newco to commence its first trade by 15 January 2024.
Mr Levin Lee Keng Weng, ACROMETA’s Executive Chairman said, “The MOU with PTSBM is a synergistic opportunity given the Group’s deep expertise in specialist engineering services as we seek to broaden the Group’s revenue stream. ACROMETA will continue to capture new business opportunities to grow and create shareholder value for its investors.”
Trend for the demand for high-grade 99.5% purity silica sand is increasing and are used in the manufacture of precision glass instruments, ophthalmic lenses and LCD screens required by many industries such as the biotechnology, electronics, and pharmaceutical industries. In construction, it is the main structural component in several construction products such as flooring, mortars, cement, roofing shingles, and asphalt. The Group is currently speaking with potential international buyers before entering into formal offtake agreements with PTSBM.
[1] Market Prices fluctuate according to prevailing market conditions.
About ACROMETA Group Limited (SGX Stock Code:43F) ACROMETA (Previously known as ACROMEC Limited) is an established specialist engineering services provider with more than 25 years of experience in the field of controlled environments.
The Group has, over the years, acquired expertise in the design and construction of facilities requiring controlled environments such as laboratories, medical and sterile facilities and cleanrooms.
ACROMETA’s business is divided into three main business segments: (i) Engineering, procurement, and construction services, specialising in architectural, and mechanical, electrical, and process works within controlled environments; (ii) Maintenance and repair services of facilities and equipment of controlled environments and their supporting infrastructure. (iii) Co-Working Laboratory business; currently operates 6,500 square feet of co-working laboratory space at The German Centre in Singapore, serving SMEs and startups.
The Group mainly serves the healthcare, biotechnology, pharmaceutical, research and academia, and electronics sectors. ACROMETA’s customers include hospitals and medical centres, government agencies, research and development companies or agencies, research and development units of multinational corporations, tertiary educational institutions, pharmaceutical companies, semiconductor manufacturing companies, and multinational engineering companies.
The Company has been listed on the Catalist board of the Singapore Exchange since 2016. For more information, please visit www.acrometa.com.
Media and Analysts Contact: ACROMETA Group Limited Ms. Cheah Lai Min Chief Financial Officer Tel: +65 6415 0574 Email: laimin.cheah@acrometa.com
This media release has been reviewed by the Company’s Sponsor, Evolve Capital Advisory Private Limited (the “Sponsor”). It has not been examined or approved by the Singapore Exchange
Securities Trading Limited (the “Exchange”), and the Exchange assumes no responsibility for the contents of this document, including the correctness of any of the statements or opinions made or reports contained in this document.
The contact person for the Sponsor is Mr. Jerry Chua, 138 Robinson Road, #13-02 Oxley Tower, Singapore 068906, jerrychua@evolvecapitalasia.com
The Board of Directors of waste-to-energy subsidiary Neo Tiew Power initiates process to place the company under Creditor’s Voluntary Liquidation
Group views action as prudent for optimal allocation of resources
The Group will continue to focus on its encouraging cash flow positive laboratory construction and co-working laboratory space businesses
ACROMETA Group Limited (ACROMETA, or the Company and together with its subsidiaries, the Group), an established specialist engineering service provider in the field of controlled environments serving mainly the healthcare, biotechnology, pharmaceutical, research and academia sectors, today announced that the Board of Directors of the Company’s indirect subsidiary, Neo Tiew Power Pte. Ltd. (NTP), had on 27 October 2023 initiated the process to place NTP under Creditors’ Voluntary Liquidation ( CVL). NTP is a wholly-owned subsidiary of Acropower Pte. Ltd., which the Company has an effective interest of 56% in.
NTP was incorporated in February 2020 to produce renewable energy by converting biomass poultry waste into green electricity by the process of pyrolysis. However, due to the Covid-19 pandemic and changes to regulations for the safe handling of potentially dangerous animal waste products, NTP has not been able to commence operations.
The Group had extended significant loans to NTP and has decided it cannot continue supporting NTP. The directors of NTP had on 27 October 2023 resolved to place NTP in Provisional Liquidation, pending its eventual liquidation. Insolvency Practitioners from Alternative Advisors Pte Ltd were appointed as Provisional Liquidators. This decision arises from the inability of NTP to continue its regular business operations by reason of their liabilities.
Mr Lim Say Chin, CEO of AcroMeta Group said, “Conversion of poultry waste to green electricity is a fundamentally promising business. However, the Covid-19 pandemic’s impact on construction as well as changes in regulations for the safe handling of animal waste products meant that the project would continue to require financial support and affect the Group’s allocation of resources.”
Mr Levin Lee Keng Weng, ACROMETA’s Executive Chairman, said, “The Board’s decision for the voluntary liquidation of NTP by Acropower reflects our current focus on expanding the laboratory construction and co-working laboratory space businesses, both of which are currently cash flow positive and show a promising future with an encouraging flow of business opportunities and projects in the last twelve months.”
In August 2023, the Group’s wholly-owned subsidiary Acromec Engineers Pte Ltd (“Acromec”) was awarded a S$19 million contract for the design and construction of a 1,500 sqm high containment biosafety level research laboratory. In October 2023, the Group’s 70% owned subsidiary company Life Science Incubator Pte Ltd (“Life Science Incubator” or “LSI”) entered into a Management Agreement (the “MA”) with HB Universal Pte Ltd, a subsidiary of Mainboard-listed Ho Bee Land Limited, to operate and manage a co-working laboratory space at Elementum, One-North, a building in the heart of Singapore’s biomedical industry district.
About ACROMETA Group Limited (SGX Stock Code:43F) ACROMETA (Previously known as ACROMEC Limited) is an established specialist engineering services provider with more than 25 years of experience in the field of controlled environments.
The Group has, over the years, acquired expertise in the design and construction of facilities requiring controlled environments such as laboratories, medical and sterile facilities and cleanrooms.
ACROMETA’s business is divided into three main business segments: (i) Engineering, procurement, and construction services, specialising in architectural, and mechanical, electrical, and process works within controlled environments; (ii) Maintenance and repair services of facilities and equipment of controlled environments and their supporting infrastructure. (iii) Co-Working Laboratory business; currently operates 6,500 square feet of co-working laboratory space at The German Centre in Singapore, serving SMEs and startups.
The Group mainly serves the healthcare, biotechnology, pharmaceutical, research and academia, and electronics sectors. ACROMETA’s customers include hospitals and medical centres, government agencies, research and development companies or agencies, research and development units of multinational corporations, tertiary educational institutions, pharmaceutical companies, semiconductor manufacturing companies, and multinational engineering companies.
The Company has been listed on the Catalist board of the Singapore Exchange since 2016. For more information, please visit www.acrometa.com.
Media and Analysts Contact: ACROMETA Group Limited, Ms. Cheah Lai Min, Chief Financial Officer, Tel: +65 6415 0574, Email: laimin.cheah@acrometa.com
This media release has been reviewed by the Company’s Sponsor, Evolve Capital Advisory Private Limited (the Sponsor). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the Exchange), and the Exchange assumes no responsibility for the contents of this document, including the correctness of any of the statements or opinions made or reports contained in this document.
The contact person for the Sponsor is Mr. Jerry Chua, 138 Robinson Road, #13-02 Oxley Tower, Singapore 068906, jerrychua@evolvecapitalasia.com.
ACROMETA Group Limited (“ACROMETA”, or the “Company” and together with its subsidiaries, the “Group”), an established specialist engineering service provider in the field of controlled environments serving mainly the healthcare, biotechnology, pharmaceutical, research and academia sectors, today announced that its 70% owned subsidiary company Life Science Incubator Pte Ltd (“Life Science Incubator” or “LSI”) has entered into a Management Agreement (the “MA”) with HB Universal Pte Ltd, a subsidiary of Mainboard-listed Ho Bee Land Limited.
The MA engages LSI to operate and manage a co-working laboratory centre at Elementum, One-North, a building in the heart of Singapore’s biomedical industry district. The MA is for an initial period of six (6) years with an option to renew the MA for a further six (6) years by mutual agreement.
The MA engages LSI to operate, manage, promote and market the co-working laboratory centre; and to provide management and consultancy services for the business. The proposed project will triple the size of LSI’s co-working laboratory space operations in Singapore. With the expanded space, the operations at Elementum will be able to attract companies that require larger Research and Development (“R&D”) space, as well as enable existing LSI customers who want to expand their R&D activities to do so.
The MA follows on the heels of LSI’s recent expansion of its co-working lab space business. On 6 April 2023, Acrometa announced to SGXNet that Life Science Incubator signed an MOU with a renowned German commercial property group to be the anchor tenant for its planned Brisbane co-working laboratory space project. On 21 March 2023, AcroMeta announced that it had signed an MOU with a Thailand industrial waste disposal company for the construction and operation of a laboratory for the testing and certification of solid waste and sludge. The construction of the laboratory would be done by Acrometa’s wholly-owned subsidiary Acromec Engineers, and LSI would operate the laboratory; with an option for joint ownership.
Mr Levin Lee Keng Weng, ACROMETA’s Executive Chairman, commented: “Biomedical sciences is an integral part of Singapore’s future economy with its focus on high value-add industries. Co-working laboratory spaces allows SMEs and startups to kickstart their R&D without incurring initial high CAPEX. There is a rising number of SMEs and startups needing co-working laboratory spaces with specialized infrastructure to conduct their R&D to bring their innovative products to the market. That is where LSI comes in.”
Mr Lee added, “Having a working partnership with Ho Bee Land, a well-known and established property developer, would solidify the LSI brand of co-working laboratory spaces. This will position us for international expansion of the LSI brand that we are planning, as there is demand for co-working laboratory space in major cities and industrial hubs globally.”
ACROMETA (Previously known as ACROMEC Limited) is an established specialist engineering services provider with more than 25 years of experience in the field of controlled environments.
The Group has, over the years, acquired expertise in the design and construction of facilities requiring controlled environments such as laboratories, medical and sterile facilities and cleanrooms.
ACROMETA’s business is divided into three main business segments: (i) Engineering, procurement, and construction services, specialising in architectural, and mechanical, electrical, and process works within controlled environments; (ii) Maintenance and repair services of facilities and equipment of controlled environments and their supporting infrastructure. (iii) Co-Working Laboratory business; currently operates 6,500 square feet of co-working laboratory space at The German Centre in Singapore, serving SMEs and startups.
The Group mainly serves the healthcare, biotechnology, pharmaceutical, research and academia, and electronics sectors. ACROMETA’s customers include hospitals and medical centres, government agencies, research and development companies or agencies, research and development units of multinational corporations, tertiary educational institutions, pharmaceutical companies, semiconductor manufacturing companies, and multinational engineering companies.
The Company has been listed on the Catalist board of the Singapore Exchange since 2016. For more information, please visit www.acrometa.com.
Media and Analysts Contact: ACROMETA Group Limited Ms. Cheah Lai Min Chief Financial Officer Tel: +65 6415 0574 Email: laimin.cheah@acrometa.com
This media release has been reviewed by the Company’s Sponsor, Evolve Capital Advisory Private Limited (the “Sponsor”). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the “Exchange”), and the Exchange assumes no responsibility for the contents of this document, including the correctness of any of the statements or opinions made or reports contained in this document.
The contact person for the Sponsor is Mr. Jerry Chua, 138 Robinson Road, #13-02 Oxley Tower, Singapore 068906, jerrychua@evolvecapitalasia.com.
ACROMETA Group Limited, an established specialist engineering service provider in the field of controlled environments serving mainly the healthcare, biotechnology, pharmaceutical, research and academia sectors, announced today that its wholly-owned subsidiary company Acromec Engineers Pte Ltd has been awarded a S$19 million contract for the design and construction of a 1,500 sqm high containment biosafety level research laboratory.
The facility is designed for research on highly infectious pathogens potentially carried by infected animals and spread through airborne transmission.
The state-of-the-art project involves the construction of a high containment biosafety laboratory using modular panels for both reliability and durability to withstand long periods of hard usage and repeated commissioning. Construction would be carried out in a ‘live’ building with many existing tenants without affecting their operations. The facility is expected to be completed and certified by 2024 and will be compliant with WHO and MOH high containment facility standards.
Mr Lim Say Chin, ACROMETA’s Executive Director and Chief Executive Officer, commented: “The award to Acromec is a testament to our engineering experience and capabilities. With its expertise and established track record in controlled environments engineering, AcroMeta is positioned to benefit from the construction of such laboratories as governments in the region strengthen their biomedical R&D capabilities to counter threats from infectious diseases.”
Acromec, the wholly-owned engineering subsidiary of the Group, is an established specialist engineering services provider with more than 25 years of experience in the field of controlled environments. It has designed and built several high biosafety level R & D laboratories and manufacturing facilities for biomedical companies, such as 10X Genomics, Integrated DNA Technologies, and GenScript.
Research laboratories a vital link in Singapore’s pandemic readiness strategy
Singapore emerged from the Covid-19 pandemic as one of the countries that scored high marks for its handling of the crisis. Every aspect of the pandemic was systematically studied, monitored, and appropriate actions taken – from procurement and cold storage of vaccines for the entire resident population, to laboratory testing and identification of each mutated variant of the virus as it evolved.
But the pandemic also revealed the need for Singapore to be prepared for future pandemics. The government has implemented the findings of the Covid-19 White Paper published on 8 March 2023 which detailed the 7 lessons to be learned from the pandemic and implemented a pandemic readiness strategy. The strategy takes a whole-country approach and involves participation by, and collaboration with the private sector as well as with the entire population.
Mr Levin Lee Keng Weng, ACROMETA’s Executive Chairman, added: “Laboratories for the testing, identification and carrying out of research with live virus is a vital link in the Singapore government’s preparedness strategy for future pandemics. These laboratories are not standard laboratories but highly specialised facilities; the design and construction of which can only be done by a handful of controlled environments experts such as Acromec.”
This media release has been reviewed by the Company’s Sponsor, Evolve Capital Advisory Private Limited. It has not been examined or approved by the Singapore Exchange Securities Trading Limited, and the Exchange assumes no responsibility for the contents of this document, including the correctness of any of the statements or opinions made or reports contained in this document.
The contact person for the Sponsor is Mr. Jerry Chua, 138 Robinson Road, #13-02 Oxley Tower, Singapore 068906, jerrychua@evolvecapitalasia.com.
ACROMETA (Previously known as ACROMEC Limited) is an established specialist engineering services provider with more than 25 years of experience in the field of controlled environments.
The Group has, over the years, acquired expertise in the design and construction of facilities requiring controlled environments such as laboratories, medical and sterile facilities and cleanrooms.
ACROMETA’s business is divided into three main business segments: (i) Engineering, procurement, and construction services, specialising in architectural, and mechanical, electrical, and process works within controlled environments; (ii) Maintenance and repair services of facilities and equipment of controlled environments and their supporting infrastructure. (iii) Co-Working Laboratory business; currently operates 6,500 square feet of co-working laboratory space at The German Centre in Singapore, serving SMEs and startups.
The Group mainly serves the healthcare, biotechnology, pharmaceutical, research and academia, and electronics sectors. ACROMETA’s customers include hospitals and medical centres, government agencies, research and development companies or agencies, research and development units of multinational corporations, tertiary educational institutions, pharmaceutical companies, semiconductor manufacturing companies, and multinational engineering companies.
The Company has been listed on the Catalist board of the Singapore Exchange since 2016. For more information, please visit www.acrometa.com.
Media and Analysts Contact:
ACROMETA Group Limited Ms. Cheah Lai Min Chief Financial Officer Tel: +65 6415 0574 Email: laimin.cheah@acrometa.com
This year’s theme, “Innovating for Sustainability: The Future of Agriculture and the Food System”, aims to highlight the importance of sustainable innovation in shaping the future of agriculture and the overall food system. The summit will provide a platform for leading experts and stakeholders in the field to exchange insights, discuss strategies, and identify solutions for pressing issues related to food security and sustainability.
Speakers at the summit include esteemed figures such as Remi Nono Womdim, Representative of the Food and Agriculture Organization of the United Nations (FAO) in Viet Nam; Nguyen Anh Phong, Director of The Information Centre for Agriculture and Rural Development (AGROINFO); and Hoang Thanh Vinh, Program Analyst at the Climate Change and Environment Unit (CCEU) at UNDP.
The speaker line up also includes Caleb Wurth, Regional Director of Southeast Asia and Oceania for the U.S. Grains Council; Timothy Loh, Regional Director, S.E. Asia & Oceania, U.S. Soybean Export Council (USSEC), Singapore; and Vu Thi Khac, Director Of Science and Quality Management Department, Institute Of Science Technology and Environment.
Key topics to be discussed during the summit include:
1. Agriculture’s Future is Driven by Sustainable Innovation 2. Managing Risk and Reacting to Volatility: Farmers’ Perspective 3. Agriculture’s Future: What to Expect? 4. Implementing New Generation Techniques for Commercial Agriculture 5. Reducing Food Loss Amid the Global Food Crisis 6. Climate Smart Agriculture: Stimulating Sustainable Production and Building New Market 7. When Sustainable Aquaculture Comes to The Rescue of Environmental Preservation 8. Smart Commodities – Enabling Supply Chain Traceability from Farm to Fork 9. How is Agriculture Providing a Safe Haven for Investment? 10. Elevating the Sensory Experience: Advancing Taste, Texture & Performance 11. Food Security: Providing Sufficient Safe, Nutritious and Healthy Food for Everyone. 12. Food Inflation and Nutrition Security Situation in Developing Asian Countries.
The summit will be co-located with The 15th Annual Global CSR & ESG Summit and Awards 2023, allowing participants to attend both events for a comprehensive and enriching experience.
For more information about the 3rd Global Food Security & Sustainability Summit 2023, please visit https://foodsecure.global
About The 3rd Global Food Security & Sustainability Summit 2023 The 3rd Global Food Security & Sustainability Summit 2023 is an annual gathering that brings together global leaders, experts, and stakeholders in the field of food security and sustainability. The summit aims to promote innovative and sustainable solutions for global food security and the future of the agriculture and food system.
